[{"id":"fe92fdc8-a6cc-4f7e-b693-b575fed6d7de","acronym":"","url":"https://clinicaltrials.gov/study/NCT01118234","created_at":"2021-01-18T04:26:04.369Z","updated_at":"2024-07-02T16:36:51.546Z","phase":"Phase 3","brief_title":"Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)","source_id_and_acronym":"NCT01118234","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD38","pipe":" | ","alterations":" Chr del(11q) • CD38 expression • TS 12","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q) • CD38 expression • TS 12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2020-01-09"}]